ITEOS THERAPEUTICS INC.
3.60
USD
(-8.86%)
04/04/2025 - 15:35
Closed 15 min delayed data - NASDAQ Stocks
| Open: | 4.07 |
| Change: | -0.35 |
| Volume: | 2,737,553 |
| Low: | 3.50 |
| High: | 4.07 |
| High / Low range: | 0.57 |
| Type: | Stocks |
| Ticker: | ITOS |
| ISIN: |
ITEOS THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
ITEOS THERAPEUTICS INC. - More news...
ITEOS THERAPEUTICS INC. - More news...
- 02/07/2023 - 12:00 iTeos to Present at SVB Securities Global Biopharma Conference
- 01/09/2023 - 12:00 iTeos Provides Business Updates and Clinical Development Plans for 2023
- 01/03/2023 - 12:00 iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
- 11/22/2022 - 12:00 iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
- 11/10/2022 - 21:01 iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
- 08/10/2022 - 20:01 iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
- 08/02/2022 - 11:00 iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
- 05/12/2022 - 20:01 iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
- 04/08/2022 - 17:00 iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
- 03/23/2022 - 20:01 iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- 02/10/2022 - 12:00 iTeos to Participate in Upcoming Investor Conferences in February
- 01/10/2022 - 12:00 iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
- 01/03/2022 - 21:01 iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
- 12/09/2021 - 21:01 iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021
- 11/10/2021 - 21:01 iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
- 11/03/2021 - 11:00 iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021
- 09/01/2021 - 11:00 iTeos Therapeutics to Participate in Upcoming September Investor Conferences
- 08/12/2021 - 11:00 iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update
- 08/05/2021 - 11:00 iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021
- 08/03/2021 - 11:00 iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021
- 07/08/2021 - 14:03 iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021
- 06/14/2021 - 11:00 iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
- 06/04/2021 - 13:00 iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
- 05/13/2021 - 20:01 iTeos Reports First Quarter 2021 Financial Results and Provides Business Update
- 05/03/2021 - 20:01 iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors
- 04/10/2021 - 12:30 iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021
- 03/24/2021 - 20:45 iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- 02/23/2021 - 12:00 iTeos to Present at Upcoming Investor Conferences in March
- 02/17/2021 - 12:00 iTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- 01/05/2021 - 12:00 iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference
